Evidence map›Paper›PMID 33096092›Full record

ReviewAmerican journal of obstetrics and gynecology2022

Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.

Sarosh Rana, Suzanne D Burke, S Ananth Karumanchi

Open access · hybridAbstract readReview
In one paragraph

Review in American journal of obstetrics and gynecology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 6 pooled it
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 6 syntheses or guidelines pooled it, 296 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Preeclampsia Screening.Diagnostics (Basel, Switzerland) · 2026
    Review
  15. Article
  16. Dialysis and Pregnancy: Optimizing Therapy for Best Maternal and Fetal Outcomes.Hemodialysis international. International Symposium on Home Hemodialysis · 2026
    Review
  17. Article
  18. Article
  19. Review
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Sarosh RanaDivision of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, The University of Chicago, Chicago, IL.
Suzanne D BurkeDepartment of Medicine, Obstetrics, and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
S Ananth KarumanchiDepartment of Medicine, Obstetrics, and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address: sananth.karumanchi@csmc.edu.
Beth Israel Deaconess Medical Center · USCedars-Sinai Medical Center · USUniversity of Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preeclampsia is a devastating medical complication of pregnancy that can lead to significant maternal and fetal morbidity and mortality. It is currently believed that there is abnormal placentation in as early as the first trimester in women destined to develop preeclampsia. Although the etiology of the abnormal placentation is being debated, numerous epidemiologic and experimental studies suggest that imbalances in circulating angiogenic factors released from the placenta are responsible for the maternal signs and symptoms of preeclampsia. In particular, circulating levels of soluble fms-like tyrosine kinase 1, an antiangiogenic factor, are markedly increased in women with preeclampsia, whereas free levels of its ligand, placental, growth factor are markedly diminished. Alterations in these angiogenic factors precede the onset of clinical signs of preeclampsia and correlate with disease severity. Recently, the availability of automated assays for the measurement of angiogenic biomarkers in the plasma, serum, and urine has helped investigators worldwide to demonstrate a key role for these factors in the clinical diagnosis and prediction of preeclampsia. Numerous studies have reported that circulating angiogenic biomarkers have a very high negative predictive value to rule out clinical disease among women with suspected preeclampsia. These blood-based biomarkers have provided a valuable tool to clinicians to accelerate the time to clinical diagnosis and minimize maternal adverse outcomes in women with preeclampsia. Angiogenic biomarkers have also been useful to elucidate the pathogenesis of related disorders of abnormal placentation such as intrauterine growth restriction, intrauterine fetal death, twin-to-twin transfusion syndrome, and fetal hydrops. In summary, the discovery and characterization of angiogenic proteins of placental origin have provided clinicians a noninvasive blood-based tool to monitor placental function and health and for early detection of disorders of placentation. Uncovering the mechanisms of altered angiogenic factors in preeclampsia and related disorders of placentation may provide insights into novel preventive and therapeutic options.

Indexed as

BiomarkersBronchopulmonary DysplasiaCardiovascular DiseasesFemaleFetal DeathFetofetal TransfusionFibrinHumansHydrops FetalisPlacenta DiseasesPlacenta Growth FactorPlacentationPre-EclampsiaPregnancyPrognosisPuerperal DisordersBiomarkersFibrinFLT1 protein, humanPlacenta Growth FactorVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1bronchopulmonary dysplasiacardiovascular diseasefetal deathfetal hydropsglomerular endotheliosishypertensionintrauterine growth restrictionplacental-derived growth factorproteinuriasoluble endoglinspiral artery remodelingtwin-to-twin transfusion syndromevascular endothelial growth factor

Identifiers

PMID33096092
PMCPMC8884164
OpenAlexW3094227856

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.